EUVIMEDEUVIMED entdecken
Crossref

Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization

Philippe Giguère iD, Nicky Akbarian, Connor Prince iD, Kednapa Thavorn, Carolina Cieniak, Matthew Granger, Linda Hamelin, Ram Vasudevan Nampoothiri iD, Michael Kennah, Natasha Kekre

European Journal of Haematology · 2026

DOI: 10.1111/ejh.70103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Philippe Giguère und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Antigens, CD19, Immunotherapy, Adoptive, Hematologic Diseases, Receptors, Chimeric Antigen. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T cells (CAR‐T) have been associated with prolonged hematotoxicity known as late immune effector cell‐associated hematologic toxicity (ICAHT), but there is limited literature on its duration and clinical implications. We conducted a retrospective review of 156 adults who received CD19‐directed CAR‐T therapy at The Ottawa Hospital between 2019 and 2024. Late ICAHT occurred in 39% (95% CI 31%–47%) of recipients, with a duration ranging from 6 to 1473 days. Cumulative incidence analysis, censoring for disease progression and death, yielded a median duration of 183 days, with 20% (95% CI 11%–38%) experiencing ICAHT lasting over 1 year. Overall survival was comparable between patients with and without late ICAHT. In univariate analysis, HEMATOTOX score was significantly associated with the development of late ICAHT. Among a subset of 13 patients assessed for resource utilization, growth factors were the primary cost driver. Patients required frequent follow‐up, with a median of 1 in every 7 days involving an in‐person healthcare encounter. Late ICAHT was a common but usually self‐limited toxicity. The 30‐day cutoff currently used to define late ICAHT should be compared to later cutoffs to evaluate whether it improves the characterization of ICAHT's clinical impact on outcomes and healthcare utilization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD19Immunotherapy, AdoptiveHematologic DiseasesReceptors, Chimeric AntigenHumansFemaleMiddle AgedIncidenceMaleAdultAgedRetrospective StudiesTreatment OutcomeT-LymphocytesHealth Resources

Stichwörter der Autor:innen

CAR‐TICAHThematologic toxicityhematology

Substanzen

Antigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Faculty of Medicine, Roger Guindon Hall, University of Ottawa, Ottawa, Ontario, Canada.
  • Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

ORCID-Profile: Philippe Giguère, Connor Prince, Ram Vasudevan Nampoothiri

Zitieren

APA

Giguère, P., Akbarian, N., Prince, C., Thavorn, K., Cieniak, C., Granger, M., Hamelin, L., Nampoothiri, R. V., Kennah, M., & Kekre, N. (2026). Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization. European Journal of Haematology. https://doi.org/10.1111/ejh.70103

Vancouver

Giguère P, Akbarian N, Prince C, Thavorn K, Cieniak C, Granger M, et al. Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization. European Journal of Haematology. 2026. doi:10.1111/ejh.70103

BibTeX
@article{Gigure2026,
  author = {Giguère, Philippe and Akbarian, Nicky and Prince, Connor and Thavorn, Kednapa and Cieniak, Carolina and Granger, Matthew and Hamelin, Linda and Nampoothiri, Ram Vasudevan and Kennah, Michael and Kekre, Natasha},
  title = {Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70103}
}
Kostenlos starten →